Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

  title={Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study},
  author={Alain C. Tissot and Patrik Maurer and Juerg Nussberger and Robert Sabat and Thomas Pfister and Stanislav Ignatenko and H D Volk and Hans Stocker and Philipp M{\"u}ller and Gary T. Jennings and Frank D Wagner and Martin F. Bachmann},
  journal={The Lancet},

Figures and Tables from this paper

Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy

Results suggest that transient AT1 vaccination is as effective as continuous treatment with ARB, not only for the attenuation of hypertension, but also for the prevention of L-NAME-induced nephropathy in SHR.

Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals

The ATRQ&bgr;-001 vaccine may provide a novel and promising method for the treatment of primary hypertension through diminishing the pressure response and inhibiting signal transduction initiated by Ang II.

Success and failure of vaccines against renin–angiotensin system components

Large studies now in progress will establish whether further modification of the immunogen or adjuvant is required to boost antibody titers, and whether this will encourage development of further vaccines directed against targets such as aldosterone or other pathways where alternative treatments are scarce or absent.

Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy

The ATRQβ-001 vaccine ameliorated streptozotocin-induced diabetic renal injury via modulating two RAS axes and inhibiting TGF-β1/Smad3 signal pathway, providing a novel, safe, and promising method to treat diabetic nephropathy.

Vaccine Targeted Alpha 1D-Adrenergic Receptor for Hypertension.

The present results demonstrate that the ADRQβ-004 vaccine may provide a novel and promising method for the treatment of hypertension and downregulated the expression of α1D-AR, but not α1A-AR.

Update on Newer Antihypertensive Medicines

AngQb vaccine in hypertensive patients showed a marked reduction in early morning blood pressure without serious adverse events and an endothelin-receptor antagonist such as bosentan significantly lowered blood pressure in patients with essential hypertension.

Clinical study on angiotensin II vaccination—the first big step

  • M. Mogi
  • Medicine
    Hypertension Research
  • 2021
The present study was a phase I/IIa study of the angiotensin II vaccine AGMG0201 in patients with mild-to-moderate essential hypertension, and the vaccine was well tolerated at both low and high doses.

Vaccine for hypertension: modulating the renin-angiotensin system.




Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.

Biochemical measurements show evidence of blockade of the renin system, but higher titres will be required to achieve a decrease in blood pressure, as shown in patients with essential hypertension.

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

AngQb reduces blood pressure in SHR to levels obtained with an ACE inhibitor, and is immunogenic and well tolerated in humans, Therefore, vaccination against angiotensin II has the potential to become a useful antihypertensive treatment providing long-lasting effects and improving patient compliance.

Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren

It is demonstrated that aliskiren, through inhibition of renin, is an effective and safe orally active BP-lowering agent and well tolerated at all doses studied.

Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A.

It is concluded that both total and active plasma renin concentrations can now be directly measured with great accuracy within 6 hours and Plasma renin activity correlated well with active renin levels.

Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension.

Different types of compliance, methods of measuring compliance, and the clinical consequences of noncompliance in hypertension are discussed.

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity

It is suggested that antibodies induced by NicQb may prevent relapses by sequestering nicotine in the blood of immunized smokers by blocking nicotine from entering the brain by induction of specific antibodies.

The Economic Impact of Hypertension

  • W. Elliott
  • Medicine
    Journal of clinical hypertension
  • 2003
Pharmacotherapy for hypertension offers a substantial potential for cost savings and pharmacyacoeconomic analyses regarding antihypertensive drug therapies, their costs, and the relevant reductions in health care expenditures are a useful framework for optimizing current strategies for hypertension management.

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.

The expression cloning of the human renin receptor complementary DNA encoding a 350-amino acid protein with a single transmembrane domain and no homology with any known membrane protein is reported, the first described for an aspartyl protease.

Circadian blood pressure: clinical implications based on the pathophysiology of its variability.

The timing of drug administration or specific drug delivery systems that lead to a greater effect at night and/or mitigate the early morning BP surge can correct abnormal circadian rhythms.